{
    "doi": "https://doi.org/10.1182/blood.V110.11.3429.3429",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=925",
    "start_url_page_num": 925,
    "is_scraped": "1",
    "article_title": "R-CHOP vs R-MiniCEOP in Elderly Patients with Diffuse Large B-Cell Lymphoma (B-DLCL) Prospectively Selected by a Multidimensional Evaluation Scale: Preliminary Results of a Randomized Study Performed by Intergruppo Italiano Linfomi (IIL). ",
    "article_date": "November 16, 2007",
    "session_type": "Lymphoma: Chemotherapy, excluding Pre-Clinical Models",
    "topics": [
        "diffuse large b-cell lymphoma",
        "older adult",
        "r-chop",
        "chemotherapy regimen",
        "anemia",
        "cyclophosphamide, doxorubicin, prednisone, and vincristine",
        "doxorubicin",
        "epirubicin",
        "failure to thrive",
        "follow-up"
    ],
    "author_names": [
        "Francesco Merli, MD",
        "Stefano Luminari, MD",
        "Alessandra Tucci, MD",
        "Patrizia Pregno, MD",
        "Maurizio Musso, MD",
        "Maurizio Martelli, MD",
        "Caterina Stelitano, MD",
        "Luca Baldini, MD",
        "Patrizio Mazza, MD",
        "Daniele Vallisa, MD",
        "Flavia Salvi, MD",
        "Elisa Barbolini, PhD",
        "Renato Scalone, MD",
        "Alice Di Rocco, MD",
        "Alberto Fragasso, MD",
        "Anna Marina Liberati, MD",
        "Chiara Bottelli, MD",
        "Lorella Orsucci, MD",
        "Fiorella Ilariucci, MD",
        "Luigi Marcheselli, PhD",
        "Massimo Federico, MD"
    ],
    "author_affiliations": [
        [
            "Intergruppo Italiano Linfomi (IIL), Italy",
            "Hematology, Azienda Ospedaliera S. Maria Nuova, Reggio Emilia, Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy",
            "Hematology, Azienda Ospedaliera S. Maria Nuova, Reggio Emilia, Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy",
            "Hematology, Azienda Ospedaliera S. Maria Nuova, Reggio Emilia, Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "Intergruppo Italiano Linfomi (IIL), Italy"
        ]
    ],
    "first_author_latitude": "37.599999999999994",
    "first_author_longitude": "-95.665",
    "abstract_text": "In 2003 the IIL started a randomized trial for the initial treatment of elderly patients with B-DLCL with the aim of comparing efficacy of standard R-CHOP chemotherapy vs less intensive R-miniCEOP regimen. The study was also aimed at assessing the usefullness of a Multidimensional Evaluation Scale (MES) for the prospective identification of patients eligible to full doses chemotherapy. Main inclusion criteria were; age \u2265 65 years, histologically confirmed B-DLCL, stage II-IV, non-frail status. Patients\u2019 frailty was assessed before randomization by MES which included: comorbidity, ADL(Activities of Daily Living), IADL (Instrumental ADL) and geriatric syndrome (Dementia, delirium, depression, incontinence, osteoporosis, falls, failure to thrive) scales. Patients were defined frail in case of \u2265 3 grade III or 1 grade IV comorbidities, score  1 ENS 27%, aaIPI \u22652 47%; clinical features were well balanced between the two regimens. Overall 70% of patients achieved CR without differences between arms (75% and 65% for R-CHOP and R-miniCEOP, respectively; p=0.173); 18 cases were withdrawn from study for early death (14) or treatment toxicity (4). Grade III-IV anemia occurred in 8% of cases (p=NS), grade III-IV neutropenia in 23% of cases (p=NS), grade III-IV infections in 4% (p=NS). After a median follow-up of 16 months for alive patients (range 1 to 52), 2-year EFS and OS were 54% (95% CI: 45% \u2013 61%) and 70% (95%CI: 61%\u2013 77%), with no differences between study arms. Analysis of MES data did not identify any comorbid condition, or ADL, or IADL scores of prognostic relevance. Among 53 patients defined frail by MES, treatment was planned with curative intent (R-CHOP, R-miniCEOP, P-VEBEC) in 28 cases. For these cases a worst outcome was observed compared to non-frail patients (2yr OS of 43% vs 70%; p=0.007). In conclusion MES represents a valid tool for identifying elderly patients with B-DLCL eligible to full doses chemotherapy and its use is recommended for future trials.The addition of Rituximab to a less intensive chemotherapy regimen (mini-CEOP) represent a good alternative to standard R-CHOP for the treatment of elderly patient with B-DLCL."
}